Home > Publications database > Circulating tryptophan-kynurenine pathway metabolites are associated with all-cause mortality among patients with stage I-III colorectal cancer. > print

001     293587
005     20250729140717.0
024 7 _ |a 10.1002/ijc.35183
|2 doi
024 7 _ |a pmid:39308420
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:168205107
|2 altmetric
037 _ _ |a DKFZ-2024-01910
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Damerell, Victoria
|b 0
245 _ _ |a Circulating tryptophan-kynurenine pathway metabolites are associated with all-cause mortality among patients with stage I-III colorectal cancer.
260 _ _ |a Bognor Regis
|c 2025
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1733729270_17662
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Feb 1;156(3):552-565
520 _ _ |a Alterations within the tryptophan-kynurenine metabolic pathway have been linked to the etiology of colorectal cancer (CRC), but the relevance of this pathway for prognostic outcomes in CRC patients needs further elucidation. Therefore, we investigated associations between circulating concentrations of tryptophan-kynurenine pathway metabolites and all-cause mortality among CRC patients. This study utilizes data from 2102 stage I-III CRC patients participating in six prospective cohorts involved in the international FOCUS Consortium. Preoperative circulating concentrations of tryptophan, kynurenine, kynurenic acid (KA), 3-hydroxykynurenine (HK), xanthurenic acid (XA), 3-hydroxyanthranilic acid (HAA), anthranilic acid (AA), picolinic acid (PA), and quinolinic acid (QA) were measured by liquid chromatography-tandem mass spectrometry. Using Cox proportional hazards regression, we examined associations of above-mentioned metabolites with all-cause mortality, adjusted for potential confounders. During a median follow-up of 3.2 years (interquartile range: 2.2-4.9), 290 patients (13.8%) deceased. Higher blood concentrations of tryptophan, XA, and PA were associated with a lower risk of all-cause mortality (per doubling in concentrations: tryptophan: HR = 0.56; 95%CI:0.41,0.76, XA: HR = 0.74; 95%CI:0.64,0.85, PA: HR = 0.76; 95%CI:0.64,0.92), while higher concentrations of HK and QA were associated with an increased risk of death (per doubling in concentrations: HK: HR = 1.80; 95%CI:1.47,2.21, QA: HR = 1.31; 95%CI:1.05,1.63). A higher kynurenine-to-tryptophan ratio, a marker of cell-mediated immune activation, was associated with an increased risk of death (per doubling: HR = 2.07; 95%CI:1.52,2.83). In conclusion, tryptophan-kynurenine pathway metabolites may be prognostic markers of survival in CRC patients.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a all‐cause mortality
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a kynurenines
|2 Other
650 _ 7 |a prognosis
|2 Other
650 _ 7 |a tryptophan
|2 Other
700 1 _ |a Klaassen-Dekker, Niels
|b 1
700 1 _ |a Brezina, Stefanie
|b 2
700 1 _ |a Ose, Jennifer
|b 3
700 1 _ |a Ulvik, Arve
|b 4
700 1 _ |a van Roekel, Eline H
|0 0000-0002-9402-2029
|b 5
700 1 _ |a Holowatyj, Andreana N
|b 6
700 1 _ |a Baierl, Andreas
|b 7
700 1 _ |a Böhm, Jürgen
|b 8
700 1 _ |a Bours, Martijn J L
|b 9
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 10
|u dkfz
700 1 _ |a de Wilt, Johannes H W
|b 11
700 1 _ |a Grady, William M
|b 12
700 1 _ |a Habermann, Nina
|b 13
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 14
|u dkfz
700 1 _ |a Keski-Rahkonen, Pekka
|b 15
700 1 _ |a Lin, Tengda
|b 16
700 1 _ |a Schirmacher, Peter
|b 17
700 1 _ |a Schrotz-King, Petra
|0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
|b 18
|u dkfz
700 1 _ |a Ulrich, Alexis B
|b 19
700 1 _ |a van Duijnhoven, Fränzel J B
|b 20
700 1 _ |a Warby, Christy A
|b 21
700 1 _ |a Shibata, David
|b 22
700 1 _ |a Toriola, Adetunji T
|0 0000-0003-1079-2606
|b 23
700 1 _ |a Figueiredo, Jane C
|b 24
700 1 _ |a Siegel, Erin M
|b 25
700 1 _ |a Li, Christopher I
|b 26
700 1 _ |a Gsur, Andrea
|0 0000-0002-9795-1528
|b 27
700 1 _ |a Kampman, Ellen
|b 28
700 1 _ |a Schneider, Martin
|b 29
700 1 _ |a Ueland, Per M
|b 30
700 1 _ |a Weijenberg, Matty P
|b 31
700 1 _ |a Ulrich, Cornelia M
|0 0000-0001-7641-059X
|b 32
700 1 _ |a Kok, Dieuwertje E
|b 33
700 1 _ |a Gigic, Biljana
|b 34
700 1 _ |a Consortium, FOCUS
|b 35
|e Collaboration Author
773 _ _ |a 10.1002/ijc.35183
|g p. ijc.35183
|0 PERI:(DE-600)1474822-8
|n 3
|p 552-565
|t International journal of cancer
|v 156
|y 2025
|x 0020-7136
856 4 _ |u https://inrepo02.dkfz.de/record/293587/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Damerell%20-%20Circulating%20tryptophan%20kynurenine%20pathway%20metabolites%20are%20associated%20with.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/293587/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Damerell%20-%20Circulating%20tryptophan%20kynurenine%20pathway%20metabolites%20are%20associated%20with.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:293587
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21